Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs.
about
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studiesMephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletionEcstasy exposure & gender: examining components of verbal memory functioning5-HTTLPR Genotype Moderates the Effects of Past Ecstasy Use on Verbal Memory Performance in Adolescent and Emerging Adults: A Pilot StudyAminoindanes--the next wave of 'legal highs'?Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research.MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014).History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS).Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug usersDepression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).Learning, Memory, and Executive Function in New MDMA Users: A 2-Year Follow-Up Study.Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processingMeta-analysis of executive functioning in ecstasy/polydrug usersMDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen PharmacologyAssociation of study characteristics with estimates of effect size in studies of ecstasy use.Safety and side effects of ayahuasca in humans--an overview focusing on developmental toxicology.A reconsideration and response to Parrott AC (2013) "Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research".fNIRS suggests increased effort during executive access in ecstasy polydrug users.Recreational 3,4-methylenedioxymethamphetamine or 'ecstasy': Current perspective and future research prospects.Dysfunctional overnight memory consolidation in ecstasy users.A prospective study of learning, memory, and executive function in new MDMA users.Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice.Cortical oxygenation suggests increased effort during cognitive inhibition in ecstasy polydrug users.Updating of working memory in ecstasy polydrug users: Findings from fNIRS.Memory-related hippocampal functioning in ecstasy and amphetamine users: a prospective fMRI study.Commentary on Halpern et al. (2011): strengthening the case against functionally significant serotonergic neurotoxicity in human MDMA (ecstasy) users.Comment on Halpern et al. (2011).'Ecstasy use, by itself, does not result in residual neurotoxicity'- a powerful argument?Residual neurocognitive features of ecstasy use: a re-interpretation of Halpern et al. (2011) consistent with serotonergic neurotoxicity.MDMA
P2860
Q24620135-587FA365-85C7-4A3D-80F0-1218EACB436CQ28069364-1AB628EC-83FC-4F2B-97CB-ECAD0CB566BEQ28483841-5DEF567B-F484-4A03-86FC-3178CA77C2B7Q28542888-7ECA1EB0-01B0-4C1A-9083-533B79FF045BQ28546929-119C9990-FFFE-45C1-ABD2-FC3873A483ABQ34199734-A964EF59-70F1-4D4C-B8E2-761C4A8F9493Q34359604-973EF833-7E4E-42AC-8B32-CFA66035CBF8Q34407992-35689388-64A5-4DCB-B14E-4AB44346A2FCQ34420092-66560633-1654-4A30-9373-340A7E31E627Q34634128-B3094320-2938-4791-979D-DF97FC2C25ADQ34656611-5BB74B5D-3E44-453E-85BD-2ADDC2BB05BFQ36352968-C18E8E42-DACF-4CF7-9DFF-92519E0D209BQ36736116-3FF4DCE6-9AB4-462E-8A56-3CC7F55A5980Q36919640-CFA249AD-6F83-47F9-ACE2-4A9DCEDA7D79Q37149027-E235EB10-3536-4342-A8A5-96C39DE45657Q37936690-9501825D-0AB5-4226-B45E-184D071050E3Q38105566-FA528874-6BA0-4A64-98FA-7C90A6CB4379Q38192959-B86C9F84-92EA-4CA0-9B9A-8EE1B04DB893Q38420994-F647DED5-4DB6-4D1B-BC69-8941ECBAD26DQ38665183-592C8A81-1308-4207-8303-4DC7CCE9CE56Q42706480-B1969D58-B65A-4FBC-9777-422E1BE4B199Q43996693-C598C76C-CD1E-46F3-8D92-53066E669E44Q47662199-62E6E2C5-2D6D-4815-84C9-FD2E183DCE9DQ47940965-DA44292E-6F90-4410-B623-1363973C4119Q48252476-397C6BA9-C058-4029-B4F9-1077082FE686Q48366250-FBF0E872-996F-4933-87EF-41710205F008Q52298270-FB2853EF-83F9-444B-A81D-40615D017EEDQ52298817-4EE30DE9-37B0-4731-BF3C-9EDB29E5970CQ52298818-786A6E29-11E1-4BC1-8A6D-5EAD8E31E5D9Q52298820-8E42D50E-A975-4D31-A36B-0A309931882DQ56961628-E9E90350-B3E7-4605-8AB6-C73EF671F10F
P2860
Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Residual neurocognitive featur ...... nimal exposure to other drugs.
@ast
Residual neurocognitive featur ...... nimal exposure to other drugs.
@en
Residual neurocognitive featur ...... nimal exposure to other drugs.
@nl
type
label
Residual neurocognitive featur ...... nimal exposure to other drugs.
@ast
Residual neurocognitive featur ...... nimal exposure to other drugs.
@en
Residual neurocognitive featur ...... nimal exposure to other drugs.
@nl
prefLabel
Residual neurocognitive featur ...... nimal exposure to other drugs.
@ast
Residual neurocognitive featur ...... nimal exposure to other drugs.
@en
Residual neurocognitive featur ...... nimal exposure to other drugs.
@nl
P2093
P2860
P1433
P1476
Residual neurocognitive featur ...... nimal exposure to other drugs.
@en
P2093
Andrea R Sherwood
David Kozin
Harrison G Pope
James I Hudson
John H Halpern
Staci Gruber
P2860
P304
P356
10.1111/J.1360-0443.2010.03252.X
P407
P577
2011-02-15T00:00:00Z